Twist Bioscience: 3 Key Takeaways for Long-Term Investors

From The Motley Fool 12 Nov 2026, 20:49 UTC 1 min read

Twist is expanding from 10 to 16 DNA writers while reinvesting its new profits, a plan that matters for anyone weighing growth against cash generation.

Full story

Continue reading this story on The Motley Fool, the publisher that reported it.

Read the full story at The Motley Fool ↗

AI tools

Written by AI from the article text. It can make mistakes; check the original story.

News

Business

National

Discover

Twist Bioscience: 3 Key Takeaways for Long-Term Investors

AI tools

Topics in this story

More from Business

Fastly vs. UiPath: Which Artificial Intelligence Stock Is a Better Buy Going into 2027?

History Says This Investing Strategy Has Never Failed After a Midterm Election

Should You Buy Alphabet Stock Now That Google Will Let Customers Run Its AI Chips in Their Own Data Centers?

Why Mobility Global Stock Gained Today

Huang and Lutnick Summoned to Testify Before Congress

Nvidia abruptly changed how it reported revenue in Singapore last year, adding to questions about its relationship with Megaspeed